Navigation Links
Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients
Date:6/27/2011

NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Product Profiles: Depression - Next generation vies for second-line patients

http://www.reportlinker.com/p0564398/Product-Profiles-Depression---Next-generation-vies-for-second-line-patients.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Introduction

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Features and benefits

* Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating depression.

* Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.

* Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.

* Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.

* Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Highlights

Datamonitor's physician survey reveals that psychiatrists perceive Forest's and Lundbeck's selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.

Valdoxan (agomelatine; Servier/Novartis) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.

Forest's Viibryd (vilazodone) has the hallmarks of a new blockbuster – a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

Your key questions answered

* What is the gold-standard drug for depression?

* How are marketed brands positioned in the depression treatment algorithm?

* Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?

* What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

MARKET DEFINITION AND OVERVIEW

Product overview

MARKETED PRODUCT PROFILES

Lexapro (escitalopram; Forest/Lundbeck)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Lexapro

Clinical and commercial attractiveness

Effexor XR (venlafaxine extended release; Pfizer)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Pristiq (desvenlafaxine; Pfizer)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Pristiq

Clinical and commercial attractiveness

Cymbalta (duloxetine; Eli Lilly/Shionogi)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Cymbalta

Clinical and commercial attractiveness

Valdoxan (agomelatine; Servier/Novartis)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Valdoxan

Clinical and commercial attractiveness

Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Abilify

Clinical and commercial attractiveness

Seroquel XR (quetiapine extended release; AstraZeneca)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Seroquel XR

Clinical and commercial attractiveness

Oleptro (trazodone extended release; Labopharm)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Other marketed drugs for depression

Remeron (mirtazapine; Merck & Co./Meiji Seika)

PIPELINE PRODUCT PROFILES

Viibryd (vilazodone; Forest)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Lu AA21004 (Lundbeck/Takeda)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

TC-5214 (Targacept/AstraZeneca)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Levomilnacipran (F2695; Forest/Pierre Fabre)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Edivoxetine (LY2216684; Eli Lilly)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Vyvanse (lisdexamfetamine; Shire)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Other drugs in development for depression

CPI-300 (bupropion; IntelGenx)

AZD6765 (AstraZeneca)

BCI-224 (sabcomeline; BrainCells)

BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe)

BCI-952 (melatonin and buspirone; Brain Cells)

BMS-820836 (Bristol-Myers Squibb/AMRI)

Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe)

Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma)

CP-601,927 (Pfizer)

EB-1010 (Euthymics Bioscience)

GLYX-13 (Naurex)

JNJ-26489112 (Johnson & Johnson)

Lu AA24530 (Lundbeck/Takeda)

OPC-34712 (Otsuka)

Orvepitant (GSK823296; GlaxoSmithKline)

PNB-01 (pipamperone and citalopram; PharmaNeuroBoost)

RG7090 (Roche)

SA4503 (cutamesine; M's Science)

Serdaxin (clavulanic acid; Rexahn Pharmaceuticals)

SSR125543 (Sanofi)

Tasimelteon (VEC-162; Vanda Pharmaceuticals)

TriRima (CX157; CeNeRx/Krenitsky Pharmaceuticals)

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX A – SURVEY INFORMATION

Physician research methodology

Physician sample breakdown

The survey questionnaire

Introduction

Section one: diagnosis and patient segmentation

Section two: treatment of major depressive disorder

Section three: product profiles

Demographics

APPENDIX B

PharmaVitae Explorer database

Contributing experts

Conferences attended

Report methodology

To order this report:

Drug and Medication Industry: Product Profiles: Depression - Next generation vies for second-line patients

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):